Envudeucitinib and the Next Wave of TYK2 Inhibition: Biologic-Level Efficacy in an Oral Psoriasis Therapy

In this Dermatology Times Expert Perspectives episode, April Armstrong, MD, MPH, examines the mechanistic rationale and emerging clinical data supporting investigational envudeucitinib as a next-generation oral therapy for moderate to severe plaque psoriasis. Central to the discussion is the agent’s highly selective binding to the TYK2 JH2 allosteric domain, demonstrating greater than 1000-fold selectivity over other Janus kinases (JAK). This level of specificity enables dose optimization with minimal off-target JAK inhibition, allowing clinicians to maximize efficacy while maintaining a favorable safety profile.

Armstrong contextualizes these pharmacologic advantages with phase 3 data presented at the 2026 American Academy of Dermatology Annual Meeting. At week 24, approximately 70% of treated patients achieved PASI 90, with roughly 40% reaching PASI 100—outcomes that approach those historically associated with biologic therapies. These findings highlight a significant shift in the oral treatment space, suggesting that next-generation TYK2 inhibitors may deliver comparable efficacy to injectable biologics while preserving the convenience of oral administration.

The discussion also highlights the clinical relevance of these outcomes in high-impact disease areas, particularly scalp psoriasis. Armstrong discusses the burden of scalp involvement, including pruritus, sleep disruption, and psychosocial impairment related to visible scaling. She notes that trauma from scratching may exacerbate disease through the Koebner phenomenon, further complicating management. Encouragingly, phase 3 data demonstrate that more than three-quarters of patients with baseline moderate to severe scalp involvement achieved clear or almost clear disease by week 24.

Collectively, these data position envudeucitinib as a promising addition to the psoriasis armamentarium, expanding therapeutic flexibility and enabling dermatologists to offer oral and biologic options with comparable confidence in both efficacy and safety.

Watch the next episode here.